These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

163 related articles for article (PubMed ID: 6810204)

  • 21. Neuroendocrine function in Huntington's disease: dopaminergic regulation of prolactin release.
    Caine E; Kartzinel R; Ebert M; Carter AC
    Life Sci; 1978 Mar; 22(10):911-8. PubMed ID: 147978
    [No Abstract]   [Full Text] [Related]  

  • 22. Pituitary function in 20 cases of prolactinoma in females.
    Eşanu C; Klepsch I; Calciu G; Bucur D; Popescu LG
    Endocrinologie; 1983; 21(2):131-9. PubMed ID: 6408728
    [TBL] [Abstract][Full Text] [Related]  

  • 23. Tuberoinfundibular dopaminergic function in Parkinson's disease.
    Franceschi M; Camerlingo M; Perego L; Bottacchi E; Truci G; Mamoli A
    Eur Neurol; 1988; 28(3):117-9. PubMed ID: 3133213
    [TBL] [Abstract][Full Text] [Related]  

  • 24. Growth hormone and prolactin secretion in liver cirrhosis: evidence for dopaminergic dysfunction.
    Borzio M; Caldara R; Ferrari C; Barbieri C; Borzio F; Romussi M
    Acta Endocrinol (Copenh); 1981 Aug; 97(4):441-7. PubMed ID: 7270004
    [No Abstract]   [Full Text] [Related]  

  • 25. Function of dopamine receptors in young-onset Parkinson's disease: prolactin response.
    Kostic VS; Marinkovic Z; Filipovic S; Momcilovic D
    Mov Disord; 1993 Apr; 8(2):227-9. PubMed ID: 8474497
    [TBL] [Abstract][Full Text] [Related]  

  • 26. Regulation of prolactin and growth hormone secretion. Site and mechanism of action of thyrotropin-releasing hormone, L-dopa and L-5-hydroxytryptophan in unanesthetized dogs.
    Richards GE; Holland FJ; Aubert ML; Ganong WF; Kaplan SL; Grumbach MM
    Neuroendocrinology; 1980; 30(3):139-43. PubMed ID: 6767993
    [TBL] [Abstract][Full Text] [Related]  

  • 27. Prolactin release in response to blockade of dopaminergic receptors and to TRH injection in developing and adult rats: role of estrogen in determining sex differences.
    Ojeda SR; Castro-Vázquez A; Jameson HE
    Endocrinology; 1977 Feb; 100(2):427-39. PubMed ID: 401731
    [TBL] [Abstract][Full Text] [Related]  

  • 28. Prolactin response to acute administration of different L-dopa plus decarboxylase inhibitors in Parkinson's disease.
    Ruggieri S; Falaschi P; Baldassarre M; D'Urso R; De Giorgio G; Rocco A; Agnoli A
    Neuropsychobiology; 1982; 8(2):102-8. PubMed ID: 7070643
    [TBL] [Abstract][Full Text] [Related]  

  • 29. Hypothalamo-pituitary function and dopamine dependence in untreated parkinsonian patients.
    Cusimano G; Capriani C; Bonifati V; Meco G
    Acta Neurol Scand; 1991 Mar; 83(3):145-50. PubMed ID: 1903236
    [TBL] [Abstract][Full Text] [Related]  

  • 30. Effects of CNS dopamine augmentation on stimulated prolactin secretion.
    Woolf PD; Leebaw WJ; Lee LA
    J Clin Endocrinol Metab; 1977 Oct; 45(4):857-60. PubMed ID: 410827
    [TBL] [Abstract][Full Text] [Related]  

  • 31. Defective central nervous system dopaminergic function in rats with estrogen-induced pituitary tumors, as assessed by plasma prolactin concentrations.
    Casanueva F; Cocchi D; Locatelli V; Flauto C; Zambotti F; Bestetti G; Rossi GL; Müller E
    Endocrinology; 1982 Feb; 110(2):590-9. PubMed ID: 6799276
    [No Abstract]   [Full Text] [Related]  

  • 32. Loss of central nervous system component of dopaminergic inhibition of prolactin secretion in patients with prolactin-secreting pituitary tumors.
    Fine SA; Frohman LA
    J Clin Invest; 1978 Apr; 61(4):973-80. PubMed ID: 659585
    [TBL] [Abstract][Full Text] [Related]  

  • 33. Prolactin secretion in chronic schizophrenia.
    Brambilla F; Guastalla A; Guerrini A; Rovere C; Legnani G; Sarno M; Riggi F
    Acta Psychiatr Scand; 1976 Oct; 54(4):275-86. PubMed ID: 826121
    [TBL] [Abstract][Full Text] [Related]  

  • 34. Differential inhibition of dopamine and bromocriptine on induced prolactin release: multiple sites for the inhibition of dopamine.
    Hanna S; Shin SH
    Neuroendocrinology; 1992 May; 55(5):591-9. PubMed ID: 1316563
    [TBL] [Abstract][Full Text] [Related]  

  • 35. Is normoreninemic essential hypertension caused by disordered central dopaminergic regulation?
    Ogihara T; Maruyama A; Naka T; Higaki J; Kanda T; Goto M; Onishi T; Kumahara Y
    Clin Exp Hypertens (1978); 1980; 2(1):89-97. PubMed ID: 6774864
    [TBL] [Abstract][Full Text] [Related]  

  • 36. Neuroendocrine responses to levodopa in multiple system atrophy (MSA).
    Kimber J; Watson L; Mathias CJ
    Mov Disord; 1999 Nov; 14(6):981-7. PubMed ID: 10584673
    [TBL] [Abstract][Full Text] [Related]  

  • 37. In vivo and in vitro modulation of growth hormone and prolactin of a mixed somatotropic-lactotropic pituitary microadenoma.
    Muechler EK; Huang KE; McDonald JV; Tang L
    Am J Obstet Gynecol; 1987 Aug; 157(2):453-5. PubMed ID: 3113252
    [TBL] [Abstract][Full Text] [Related]  

  • 38. Different responses of growth hormone secretion to guanfacine, bromocriptine, and thyrotropin-releasing hormone in acromegalic patients with pure growth hormone (GH)-containing and mixed GH/prolactin-containing pituitary adenomas.
    Lamberts SW; Klijn JG; van Vroonhoven CC; Stefanko SZ
    J Clin Endocrinol Metab; 1985 Jun; 60(6):1148-53. PubMed ID: 3923021
    [TBL] [Abstract][Full Text] [Related]  

  • 39. TRH test and the continuous dopaminergic stimulation in complicated Parkinson's disease.
    Lestingi L; Bonifati V; Stocchi F; Antonozzi I; Meco G
    Eur Neurol; 1992; 32(2):65-9. PubMed ID: 1563463
    [TBL] [Abstract][Full Text] [Related]  

  • 40. Human pituitary adenomas with hypersecretion of TSH and prolactin. Evidence that receptor sites for dopamin may be absent on TSH producing while present on prolactin producing cells.
    Werner S
    Horm Metab Res; 1979 Jul; 11(7):452-3. PubMed ID: 113330
    [No Abstract]   [Full Text] [Related]  

    [Previous]   [Next]    [New Search]
    of 9.